Status:
COMPLETED
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Lead Sponsor:
German CLL Study Group
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as bendamustine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. ...
Detailed Description
OBJECTIVES: Primary * Determine the response rate (remission rate) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) treated with bendamustine and mitoxantrone hydroc...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Cytologically and immunophenotypically confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL)
- Relapsed or refractory disease
- PATIENT CHARACTERISTICS:
- No known hypersensitivity to any of the study medications
- No uncontrolled infection
- No impaired organ function
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00274963
Start Date
October 1 2004
End Date
October 1 2009
Last Update
May 11 2018
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Humaine - Clinic
Bad Saarow, Germany, 15526
2
Schwerpunktpraxis fuer Haematologie und Internistische Onkologie
Berlin, Germany, D-10117
3
Praxis Fuer Haematologie Internistische Onkologie
Cologne, Germany, D-50677
4
Internistische Gemeinschaftspraxis - Halle
Halle, Germany, 06110